Partnering to discover if the answer to coronary artery disease lies within.
One in every four deaths in the US are attributable to heart disease, 610,000 people per annum1 . While treatment options continue to flourish, scientific discovery of the specific biological triggers for coronary events remains in its infancy.
Our client, an innovative emerging company, is seeking to overcome this gap with the development of a novel coronary artery blood sampling system. The system seeks to collect biological data directly from a diseased coronary artery using a sophisticated blood harvesting device.
At start-up, the company was initially seeking to develop and prove its theories on blood sampling and sought assistance to support its staged development. Having worked with over 100+ early stage companies, the Creganna Medical design team were chosen as the optimum partner to develop this innovative system while simultaneously providing the flexibility and understanding for a company navigating clinical milestones and funding rounds.
Our design team has supported this product through the design process, through regulatory approval and it is currently in short-run manufacture. The Creganna design team worked to aggressive milestone targets and were key to the development of a truly revolutionary solution.
The client's novel design features unique, deployable mixing structures and, having achieved CE certification, the company is now engaged in a programme of clinical studies to build a definitive database of biomarkers associated with coronary artery disease. Creganna Medical is pleased to continue to be a key supplier to the company moving forward.
Partner of choice for the design and manufacture of minimally invasive access and delivery systems